Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer

被引:12
|
作者
Luu, Andreas Minh [1 ]
Hoehn, Philipp [1 ]
Vogel, SinaRabea [1 ]
Reinacher-Schick, Anke [2 ]
Munding, Johanna [3 ]
Uhl, Waldemar [1 ]
Braumann, Chris [1 ]
机构
[1] Ruhr Univ Bochum, St Josef Hosp, Dept Gen & Visceral Surg, Bochum, Germany
[2] Ruhr Univ Bochum, St Josef Hosp, Dept Oncol, Bochum, Germany
[3] Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Inst Pathol, Bochum, Germany
关键词
Pathologic complete response; ypT0; Pancreatic cancer; Hepatic metastases; FOLFIRINOX; RESECTION; OUTCOMES; THERAPY;
D O I
10.1159/000497827
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: Pancreatic cancer is a lethal disease and often asymptomatic. Therefore, it is most often diagnosed at an advanced stage. The standard approach in a metastasized tumor stage is palliative chemotherapy. However, the prognosis remains extremely poor. Case Report: We present the case of a patient who was diagnosed with a cancer of the head of the pancreas with hepatic metastases. After receiving palliative intended chemotherapy with the FOLFIRINOX regimen, staging computed tomography revealed the disappearance of the liver metastases and local resectability of the pancreatic head tumor. The patient underwent an uneventful Whipple's procedure. Surprisingly, pathohistological investigation revealed a complete pathological response. Conclusion: Pathological complete response after FOLFIRINOX treatment in hepatic metastasized pancreatic cancer is extremely rare. It enables surgical resection and increases the survival rate significantly.
引用
收藏
页码:387 / 390
页数:4
相关论文
共 50 条
  • [1] Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation
    Okada, Kenjiro
    Uemura, Kenichiro
    Okamoto, Wataru
    Sumiyoshi, Tatsuaki
    Shintakuya, Ryuta
    Otsuka, Hiroyuki
    Serikawa, Masahiro
    Ishii, Yasutaka
    Arihiro, Koji
    Takahashi, Shinya
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (02) : 283 - 288
  • [2] Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation
    Kenjiro Okada
    Kenichiro Uemura
    Wataru Okamoto
    Tatsuaki Sumiyoshi
    Ryuta Shintakuya
    Hiroyuki Otsuka
    Masahiro Serikawa
    Yasutaka Ishii
    Koji Arihiro
    Shinya Takahashi
    Clinical Journal of Gastroenterology, 2023, 16 : 283 - 288
  • [3] FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer
    Luu, Andreas Minh
    Herzog, Torsten
    Hoehn, Philipp
    Reinacher-Schick, Anke
    Munding, Johanna
    Uhl, Waldemar
    Braumann, Chris
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (02) : E9 - E12
  • [4] Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment
    Shelemey, Paige T.
    Amaro, Carla P.
    Ng, Danny
    Falck, Vincent
    Tam, Vincent C.
    BMJ CASE REPORTS, 2021, 14 (05)
  • [5] Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review
    Mišo Gostimir
    Sean Bennett
    Terence Moyana
    Harman Sekhon
    Guillaume Martel
    BMC Cancer, 16
  • [6] Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review
    Gostimir, Miso
    Bennett, Sean
    Moyana, Terence
    Sekhon, Harman
    Martel, Guillaume
    BMC CANCER, 2016, 16
  • [7] Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer
    Golan, Talia
    Barenboim, Alex
    Lahat, Guy
    Nachmany, Ido
    Goykhman, Yacov
    Shacham-Shmueli, Einat
    Halpern, Naama
    Brazowski, Eli
    Geva, Ravit
    Wolf, Ido
    Goldes, Yuri
    Ben-Haim, Menahem
    Klausner, Joseph M.
    Lubezky, Nir
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (10) : 3963 - 3970
  • [8] Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer
    Talia Golan
    Alex Barenboim
    Guy Lahat
    Ido Nachmany
    Yacov Goykhman
    Einat Shacham-Shmueli
    Naama Halpern
    Eli Brazowski
    Ravit Geva
    Ido Wolf
    Yuri Goldes
    Menahem Ben-Haim
    Joseph M. Klausner
    Nir Lubezky
    Annals of Surgical Oncology, 2020, 27 : 3963 - 3970
  • [9] Pathological Response Predicts Survival after Pancreatectomy following Neoadjuvant FOLFIRINOX for Pancreatic Cancer
    Jeon, Hyun Jeong
    Jeong, Hye Jeong
    Lim, Soo Yeun
    Yoon, So Jeong
    Kim, Hongbeom
    Han, In Woong
    Heo, Jin Seok
    Shin, Sang Hyun
    CANCERS, 2023, 15 (01)
  • [10] Neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer
    Shahda, Safi
    House, Michael G.
    Schmidt, C. Max
    Nakeeb, Attila
    Sehdev, Amikar
    Lin, Jingmei
    Cramer, Harvey M.
    Tong, Yan
    Flynn, Janet R.
    Zyromski, Nicholas J.
    O'Neil, Bert H.
    CANCER RESEARCH, 2016, 76